belimumab

Home
Ligands
belimumab

GtoPdb Ligand ID: 6887

Synonyms: Benlysta® | hBlySmAb-1.1 | LimphoStat-B | lymphostat-B

belimumab is an approved drug (FDA (2011), EMA (2011))

Comment: Belimumab is a monoclonal antibody targeting TNFSF13B (BAFF; BLyS) [1,4] , an immunostimulant essential for normal B cell maintenance and humoral immunity [5], and which is reported to be elevated in systemic lupus erythematosus (SLE) and other autoimmune diseases

View more information in the IUPHAR Pharmacology Education Project: belimumab

References
1. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L et al.. (2003) Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum, 48 (11): 3253-65. [PMID:14613291]
2. Dörner T. (2006) Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl, 77: 3-11. [PMID:16652439]
3. Lutalo PM, D'Cruz DP. (2014) Update on belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther, 14 (11): 1701-8. [PMID:25303323]
4. Sabahi R, Anolik JH. (2006) B-cell-targeted therapy for systemic lupus erythematosus. Drugs, 66 (15): 1933-48. [PMID:17100405]
5. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H et al.. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med, 189 (11): 1747-56. [PMID:10359578]

References

1. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L et al.. (2003)
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
Arthritis Rheum, 48 (11): 3253-65. [PMID:14613291]

2. Dörner T. (2006)
Crossroads of B cell activation in autoimmunity: rationale of targeting B cells.
J Rheumatol Suppl, 77: 3-11. [PMID:16652439]

3. Lutalo PM, D'Cruz DP. (2014)
Update on belimumab for the management of systemic lupus erythematosus.
Expert Opin Biol Ther, 14 (11): 1701-8. [PMID:25303323]

4. Sabahi R, Anolik JH. (2006)
B-cell-targeted therapy for systemic lupus erythematosus.
Drugs, 66 (15): 1933-48. [PMID:17100405]

5. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H et al.. (1999)
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth.
J Exp Med, 189 (11): 1747-56. [PMID:10359578]